Ultrasound-guided Supraclavicular Brachial Plexus Blockade
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by University of Manitoba.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
University of Manitoba
Information provided by:
University of Manitoba
ClinicalTrials.gov Identifier:
NCT00523055
First received: August 28, 2007
Last updated: April 25, 2011
Last verified: April 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Pain Clinic patients undergoing physiotherapy for rehabilitation often have arm freezing performed. The quality of physiotherapy is felt to be superior with good pain control. The quality of the freezing is felt to be better when it is done with ultrasound guidance. We are able to use less drug to achieve the same result. For this reason, we are doing a study to look at the level of freezing drug that accumulates in the body. We feel that the drug levels will be significantly different. We also feel that the time-to-peak drug level will be different than with traditional arm freezing procedures.
| Condition | Intervention |
|---|---|
|
Pain |
Drug: Lidocaine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | Ultrasound-guided Supraclavicular Brachial Plexus Blockade: A Pharmacokinetic Study of Lidocaine and Adrenaline |
Resource links provided by NLM:
Further study details as provided by University of Manitoba:
Primary Outcome Measures:
- Lidocaine drug level [ Time Frame: 40 minutes ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- brachial plexus block quality [ Time Frame: 30 minutes ] [ Designated as safety issue: Yes ]
- Physiotherapy quality [ Time Frame: within 2 hours ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 30 |
| Study Start Date: | May 2008 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Lidocaine
Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- patients undergoing brachial plexus anesthesia as part of disease management who have consented to participate in the study
Exclusion Criteria:
- Contraindication to brachial plexus anesthesia
- Informed consent not obtained
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00523055
Contacts
| Contact: Eric N Sutherland, MD | 2042849796 | ericsuds@mts.net |
Locations
| Canada, Manitoba | |
| Health Sciences Pain Management Centre | Recruiting |
| Winnipeg, Manitoba, Canada, R3P1S4 | |
| Sub-Investigator: Craig Haberman, MD | |
| Sub-Investigator: Ryan Amadeo, MD | |
Sponsors and Collaborators
University of Manitoba
Investigators
| Principal Investigator: | Eric N Sutherland, MD | University of Manitoba |
More Information
Publications:
| Responsible Party: | Eric Sutherland, University of Manitoba |
| ClinicalTrials.gov Identifier: | NCT00523055 History of Changes |
| Other Study ID Numbers: | B2007:078 |
| Study First Received: | August 28, 2007 |
| Last Updated: | April 25, 2011 |
| Health Authority: | Canada: University of Manitoba Research Ethics Board |
Keywords provided by University of Manitoba:
|
Pain Brachial Plexus Anesthesia Plasma Lidocaine Levels Ultrasound |
Additional relevant MeSH terms:
|
Lidocaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions |
Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anti-Arrhythmia Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 22, 2013